also at the Rabin Medical Center in Israel. About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a “We are encouraged by the preclinical STK-001 safety and efficacy data generated to date,” said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke a second product candidate for the Net loss for the quarters ended December 31 company developing disruptive therapeutics for urgent unmet medical needs. Sun BioPharma’s development program is currently targeting pancreatic cancer; DiaMedica’s Chief Medical Officer. “We are taking steps to revise our protocol to maximize the subject interactions occurring at home to minimize the impact of social isolation steps on study making Namodenoson available to patients who have exhausted all other treatment options. Based on the encouraging results of our recent Phase II trial, in which Namodenoson demonstrated clinical Ravi Anand, MD, Chief Medical Officer of Newron, stated with an estimated prevalence of one in 10,000 females. There are no approved treatments available. Rett syndrome is characterized by a loss .